Clinical Trial Update: Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating afatinib with chemotherapy as conversion therapy for unresectable EGFR-mutant Stage III non-small cell lung cancer; currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (Gilotrif) (afatinib)
• Chemotherapy (chemotherapy)

Snippet

Sponsor: Shandong Public Health Clinical Center | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: RECRUITING